IL302460A - Antibodies against SARS-COV-2 antigen and related compositions and methods - Google Patents

Antibodies against SARS-COV-2 antigen and related compositions and methods

Info

Publication number
IL302460A
IL302460A IL302460A IL30246023A IL302460A IL 302460 A IL302460 A IL 302460A IL 302460 A IL302460 A IL 302460A IL 30246023 A IL30246023 A IL 30246023A IL 302460 A IL302460 A IL 302460A
Authority
IL
Israel
Prior art keywords
seq
polypeptide
set forth
amino acid
acid sequence
Prior art date
Application number
IL302460A
Other languages
English (en)
Hebrew (he)
Original Assignee
Adaptive Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptive Biotechnologies Corp filed Critical Adaptive Biotechnologies Corp
Publication of IL302460A publication Critical patent/IL302460A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL302460A 2020-10-30 2021-10-29 Antibodies against SARS-COV-2 antigen and related compositions and methods IL302460A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063108158P 2020-10-30 2020-10-30
US202063108791P 2020-11-02 2020-11-02
US202063112096P 2020-11-10 2020-11-10
US202163190097P 2021-05-18 2021-05-18
PCT/US2021/057452 WO2022094343A1 (en) 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods

Publications (1)

Publication Number Publication Date
IL302460A true IL302460A (en) 2023-06-01

Family

ID=81384373

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302460A IL302460A (en) 2020-10-30 2021-10-29 Antibodies against SARS-COV-2 antigen and related compositions and methods

Country Status (8)

Country Link
US (1) US20230382979A1 (enExample)
EP (1) EP4237443A4 (enExample)
JP (1) JP2023548471A (enExample)
AU (1) AU2021369409A1 (enExample)
BR (1) BR112023008365A2 (enExample)
CA (1) CA3200263A1 (enExample)
IL (1) IL302460A (enExample)
WO (1) WO2022094343A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981481A (zh) * 2023-01-10 2025-11-18 萨那生物技术股份有限公司 Cd19特异性抗体构建体以及它们的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODY
WO2019075433A1 (en) * 2017-10-13 2019-04-18 Adimab, Llc ANTIBODIES AGAINST SYNCYTIAL RESPIRATORY VIRUS AND METHODS FOR THEIR GENERATION AND USE
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno

Also Published As

Publication number Publication date
CA3200263A1 (en) 2022-05-05
JP2023548471A (ja) 2023-11-17
EP4237443A4 (en) 2025-06-04
US20230382979A1 (en) 2023-11-30
WO2022094343A1 (en) 2022-05-05
BR112023008365A2 (pt) 2023-12-12
AU2021369409A9 (en) 2024-10-10
AU2021369409A1 (en) 2023-06-15
EP4237443A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
US20250282863A1 (en) Antibody constructs for msln and cd3
US20250163177A1 (en) Bispecific t cell engaging antibody constructs
TW201348256A (zh) Ｃｘ３ｃｒ１－結合多肽
US20240228596A1 (en) Pan-specific corona virus binders
CA3249283A1 (en) BINDERS OF SARBECOVIRUS SPICULE S2 SUBUNITS
JP7805362B2 (ja) Ｃｄ３に結合するポリペプチド構築物
CN116496389A (zh) 用于治疗hbv感染及相关疾病的表位肽及抗体
US20230406887A1 (en) Antigen binding domain with reduced clipping rate
CA3198333A1 (en) Antibody compositions for treatment of corona virus infection
US20230382979A1 (en) Anti-sars-cov-2 antigen antibodies and related compositions and methods
US20260116983A1 (en) Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use
WO2024058987A2 (en) Polypeptides effective against multiple coronaviruses
CA3211935A1 (en) Anti-vaccinia virus antigen antibodies and related compositions and methods
US20240391980A1 (en) Anti-Human Astrovirus Antibodies and Related Compositions and Methods
CA3107192C (en) Antibody constructs for cldn18.2 and cd3
AU2024302269A1 (en) T cell engager masking molecules
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus
WO2023025813A1 (en) Neutralizing antibodies directed to sars-cov-2 spike protein
CN117836321A (zh) 抗牛痘病毒抗原抗体以及相关组合物和方法
EA050517B1 (ru) Антигенсвязывающий домен с пониженной скоростью расщепления